Black Diamond Therapeutics BDTX
$ 2.45
0.82%
Quarterly report 2024-Q3
added 11-05-2024
Black Diamond Therapeutics Balance Sheet 2011-2024 | BDTX
Annual Balance Sheet Black Diamond Therapeutics
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-30.9 M | -6.18 M | -37.3 M | -19.2 M | -155 M | -51.7 M | -7.88 M | - | - | - | - | - | - |
Long Term Debt |
22.2 M | 25.3 M | 28.1 M | 7.69 M | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
3.11 M | 2.84 M | 320 K | 1.05 M | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 7.69 M | 201 M | 64.8 M | 12.5 M | - | - | - | - | - | - |
Total Current Liabilities |
19.6 M | 15.3 M | 23.6 M | 14.2 M | 4.86 M | - | - | - | - | - | - | - | - |
Total Liabilities |
41.8 M | 40.6 M | 51.8 M | 21.9 M | 205 M | 67.4 M | 14.7 M | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-417 M | -335 M | -244 M | -118 M | -51 M | -15.7 M | -6.78 M | - | - | - | - | - | - |
Total Assets |
159 M | 156 M | 248 M | 330 M | 158 M | 51.8 M | 8.02 M | - | - | - | - | - | - |
Cash and Cash Equivalents |
56.2 M | 34.3 M | 65.8 M | 34.6 M | 155 M | 51.7 M | - | - | - | - | - | - | - |
Book Value |
117 M | 116 M | 196 M | 308 M | -47.2 M | -15.5 M | -6.68 M | - | - | - | - | - | - |
Total Shareholders Equity |
117 M | 116 M | 196 M | 308 M | -47.2 M | -15.5 M | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Black Diamond Therapeutics
2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
19.7 M | 20.5 M | 22.2 M | 23 M | 23.8 M | 24.5 M | 25.3 M | 26 M | 26.8 M | 27.5 M | 28.1 M | 28.8 M | 13.4 M | 13.8 M | 7.69 M | 7.69 M | 7.69 M | 7.69 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
40.5 M | 39 M | 41.8 M | 38.1 M | 37.7 M | 37.4 M | 40.6 M | 47.2 M | 46.5 M | 46.9 M | 51.8 M | 55.2 M | 36.9 M | 32.5 M | 21.9 M | 21.9 M | 21.9 M | 21.9 M | 4.88 M | 4.88 M | 4.88 M | 4.88 M | 6.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-471 M | -456 M | -417 M | -398 M | -375 M | -356 M | -335 M | -314 M | -292 M | -269 M | -244 M | -218 M | -183 M | -149 M | -118 M | -118 M | -118 M | -118 M | -51 M | -51 M | -51 M | -51 M | -15.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
138 M | 150 M | 159 M | 172 M | 120 M | 136 M | 156 M | 180 M | 199 M | 219 M | 248 M | 274 M | 288 M | 313 M | 330 M | 330 M | 330 M | 330 M | 158 M | 158 M | 158 M | 158 M | 51.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
23.4 M | 32.8 M | 56.2 M | 58 M | 41.9 M | 39.1 M | 34.3 M | 54 M | 55.9 M | 54.1 M | 65.8 M | 46.6 M | 37.3 M | 14.1 M | 35.8 M | 34.6 M | 34.6 M | 34.6 M | 155 M | 155 M | 155 M | 155 M | 51.7 M | - | - | - | 7.88 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
97.4 M | 111 M | 117 M | 134 M | 82.2 M | 98.2 M | 116 M | 133 M | 152 M | 173 M | 196 M | 219 M | 251 M | 281 M | 308 M | 308 M | 308 M | 308 M | 153 M | 153 M | 153 M | 153 M | 45.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
97.4 M | 111 M | 117 M | 134 M | 82.2 M | 98.2 M | 116 M | 133 M | 152 M | 173 M | 196 M | 219 M | 251 M | 281 M | 308 M | 308 M | 308 M | 308 M | -47.2 M | -47.2 M | -47.2 M | -47.2 M | -15.5 M | - | - | - | -6.68 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency